<DOC>
	<DOCNO>NCT01088620</DOCNO>
	<brief_summary>The purpose trial estimate therapeutic efficacy experimental target regimen include EGFR antibody panitumumab ( combination pemetrexed cisplatin ) relation standard combination patient KRAS wild-type stage IIIB IV primary nonsquamous non-small cell lung cancer . It expect progression free survival rate 6 month improve targeted regimen .</brief_summary>
	<brief_title>Panitumumab Plus Pemetrexed Cisplatin ( PemCisP ) Versus PemCis First-line Treatment Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm diagnosis inoperable stage IIIB IV primary pulmonary nonsquamous NSCLC ( accord UICC stag valid 2008 ) Sufficient representative sample material KRAS analysis Wildtype KRAS Informed consent patient Aged least 18 year WHO Performance Status 02 At least one unidimensional , measurable tumour parameter accord RECIST Life expectancy al least 12 week Adequate haematological , hepatic , renal metabolic function parameter : Leukocytes &gt; 3000/mm³ , ANC ≥ 1500/mm3 , platelet ≥ 100,000/mm3 , Creatinine clearance ≥ 50 ml/min serum creatinine ≤ 1.5 x upper limit normal Bilirubin ≤ 1.5 x upper limit normal , GOTGPT ≤ 2.5 x upper limit normal absence liver metastasis , ≤ 5 x upper limit normal presence liver metastasis , AP ≤ 5 x upper limit normal Magnesium ≥ low limit normal ; calcium ≥ low limit normal Prior chemotherapy Clinically manifest , uncontrolled brain metastasis Prior radiotherapy parameter measure Peripheral neuropathy NCI grade &gt; 1 Subject pregnant breast feeding , plan become pregnant within 6 month end treatment . Subject ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment ( adequate : oral contraceptive , intrauterine device barrier method conjunction spermicidal jelly ) . Serious concurrent disease . Major surgery within last 4 week recruitment Ontreatment participation clinical study period 30 day prior inclusion . Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrolment . Ongoing active infection , include active tuberculosis know infection human immunodeficiency virus . Superior vena cava syndrome contraindicate hydration . History interstitial lung disease , e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . Patient mild moderate renal insufficiency unable interrupt salicylate ( like aspirin ) nonsteroidal antiinflammatory drug ( NSAIDS ) 5day period start 2 day administration pemetrexed ( 8day period longacting agent piroxicam ) . Exception : Low dose aspirin ( acetyl salicylic acid ) intake 150 mg per day permit without interruption . Presence clinically significant thirdspace fluid collection , example , ascites pleural effusion control drainage procedure Inability unwillingness take folic acid , vitamin B12 supplementation dexamethasone ( equivalent corticosteroid ) ; inability comply protocol study relate procedure Prior concurrent malignancy ( ≤ 5 year prior enrolment study ) except nonmelanoma skin cancer cervical carcinoma FIGO stage 01 patient continuously diseasefree Known allergic reaction study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Stage IIIb IV</keyword>
	<keyword>Nonsquamous</keyword>
	<keyword>KRAS-Wildtype</keyword>
</DOC>